CA 19-9


Also found in: Wikipedia.

CA 19-9

abbreviation for cancer antigen 19-9 antigen, a blood tumor marker for pancreatic, hepatobiliary and colorectal cancer. This tumor marker is used in diagnosis, evaluation of a patient's response to treatment, and surveillance of the disease.

CA 19-9

A tumour-associated carbohydrate antigen located on the sialylated Lewis A blood group antigen (individuals who are genotypically Lewis a-b-[Lea-b-] comprise 5% of the population and cannot synthesize the antigen).

Serum levels
> 37 U/mL occur in 72–100% of patients with pancreatic cancer; 97% of those with levels > 1000 U/m; 65% of those with hepatocellular carcinoma; 20+% of those with gastric cancer; 20% of those with colorectal cancer. Because CA19-9 is also elevated in benign conditions (e.g., obstructive jaundice, liver disease, acute and chronic pancreatitis, diabetes, interstitial lung disease, collagen vascular disease, cholecystitis and cirrhosis of the liver), it is not widely used as a cancer marker. At one time it was regarded as useful in differentiating mesothelioma (in which it is negative) from various adenocarcinomas (in which it is positive).

CA 19-9 (Cancer antigen 19-9)

A tumor marker associated with pancreatic cancer.
Mentioned in: Tumor Markers
References in periodicals archive ?
AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid), Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood, PAP, PSA, Thyroglobulin, Vitamin B-12.
The patient's CA 19-9, CEA and Chromogranine A levels were all normal.
CA 19-9 was elevated (Table) with concomitantly increased bilirubin (6.
The clinical utility of the CA 19-9 tumor-associated antigen.
Elevated CA 19-9 level is typical for ductal pancreas adenocarcinoma; however, a slight increase of CA 19-9 levels can be observed in 20% of AIP patients as well, but rarely elevated above 200 U/ml [7, 10].
11 for AFP, [beta]-hCG, CA 125, CA 15-3, CA 19-9 and CEA to determine whether the clinical information provided with the request corresponded to the BPAC guidelines of appropriate use.
CA 19-9 and CEA levels dropped following the procedure, but were still elevated at 49 and 4.
Tumor Marker Control is intended for use as an assayed control serum to monitor the precision of laboratory-testing procedures for the analysis of AFP, CA 15-3, CA 19-9, CA 125, CEA, Ferritin, HE4, PSA, and Free PSA.
CA 19-9 (cancer antigen 19-9) or GICA (gastrointestinal cancer antigen) is a glycolipid with unknown biological function, which was the first successful tumour marker used for serological diagnosis of pancreatic cancer (90,91).
Additional patient-indicated tumor marker studies may include the following: CA 19-9, CA 15.
dagger]) CA 19-9 is a sialylated lacto-N-fucopentose II molecule that is related to the Lewis a (Lea) blood group substance.
A tumor marker panel consisting of prostate specific antigen (PSA), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9) and alpha fetoprotein (AFP) showed a mildly elevated PSA and CA 19-9.